Unlocking the resorption potential of cannabidiolic acid: A comprehensive in vitro and in vivo bioavailability study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00085823" target="_blank" >RIV/00023001:_____/25:00085823 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/60461373:22330/25:43932269

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0378517325009470?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0378517325009470?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ijpharm.2025.126110" target="_blank" >10.1016/j.ijpharm.2025.126110</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Unlocking the resorption potential of cannabidiolic acid: A comprehensive in vitro and in vivo bioavailability study

Popis výsledku v původním jazyce

Phytocannabinoids, unique secondary metabolites of the plant Cannabis sativa L., are characterised by a wide spectrum of pharmacological activities and their use in medicine and food industry has increased exponentially in recent years. In this study, the bioavailability of 10 representatives of neutral cannabinoids and cannabinoid acids was evaluated using an in vitro model of Caco-2 cells, as well as in vivo using an inbred mouse model. In the context of a possible increase in bioavailability, the influence of matrix components associated with the &apos;cannabis synergy&apos; phenomenon was also investigated. The analysis of cannabinoids and non-cannabinoid matrix components was performed using a sensitive and validated method based on ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry (UHPLC-HRMS/MS). As a proof of concept for testing formulation effects on bioavailability, the most abundant cannabinoid and its corresponding acid (CBD and CBDA) were encapsulated in nanomicelles and the effect of the formulation was tested both in vitro and in vivo. The experiments showed that cannabidiolic acid (CBDA) had a significantly better bioavailability compared to cannabidiol (CBD), especially in the in vivo model (CBDA concentrations in mouse plasma were approximately two orders of magnitude higher than those of CBD under the same dosing conditions). These results demonstrate the great potential of CBDA as a previously overlooked and therapeutically underutilized substance.

Název v anglickém jazyce

Unlocking the resorption potential of cannabidiolic acid: A comprehensive in vitro and in vivo bioavailability study

Popis výsledku anglicky

Phytocannabinoids, unique secondary metabolites of the plant Cannabis sativa L., are characterised by a wide spectrum of pharmacological activities and their use in medicine and food industry has increased exponentially in recent years. In this study, the bioavailability of 10 representatives of neutral cannabinoids and cannabinoid acids was evaluated using an in vitro model of Caco-2 cells, as well as in vivo using an inbred mouse model. In the context of a possible increase in bioavailability, the influence of matrix components associated with the &apos;cannabis synergy&apos; phenomenon was also investigated. The analysis of cannabinoids and non-cannabinoid matrix components was performed using a sensitive and validated method based on ultra-high performance liquid chromatography coupled with high-resolution tandem mass spectrometry (UHPLC-HRMS/MS). As a proof of concept for testing formulation effects on bioavailability, the most abundant cannabinoid and its corresponding acid (CBD and CBDA) were encapsulated in nanomicelles and the effect of the formulation was tested both in vitro and in vivo. The experiments showed that cannabidiolic acid (CBDA) had a significantly better bioavailability compared to cannabidiol (CBD), especially in the in vivo model (CBDA concentrations in mouse plasma were approximately two orders of magnitude higher than those of CBD under the same dosing conditions). These results demonstrate the great potential of CBDA as a previously overlooked and therapeutically underutilized substance.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

<a href="/cs/project/GA22-20860S" target="_blank" >GA22-20860S: Protizánětlivé účinky bioaktivních sloučenin izolovaných z Cannabis sativa L.</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International journal of pharmaceutics

ISSN

0378-5173

e-ISSN

1873-3476

Svazek periodika

684

Číslo periodika v rámci svazku

November 2025

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

11

Strana od-do

"art. no. 126110"

Kód UT WoS článku

001565870200001

EID výsledku v databázi Scopus

2-s2.0-105013981282